Literature DB >> 19321619

Influenza A virus lacking M2 protein as a live attenuated vaccine.

Shinji Watanabe1, Tokiko Watanabe, Yoshihiro Kawaoka.   

Abstract

Mutant influenza virus that lacks the transmembrane and cytoplasmic tail domains of M2 (M2 knockout [M2KO]) is attenuated in both cell culture and mice. Here, we examined the potency of M2KO influenza virus as a live attenuated influenza vaccine. M2KO virus grew as efficiently as the wild-type virus in cells stably expressing the wild-type M2, indicating the feasibility of efficient vaccine production. Mice intranasally vaccinated with M2KO virus developed protective immune responses and survived a lethal challenge with the wild-type virus, suggesting that the M2KO virus has potential as a live attenuated vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321619      PMCID: PMC2681926          DOI: 10.1128/JVI.00450-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

Authors:  Iain Stephenson; Karl G Nicholson; Anthony Colegate; Audino Podda; John Wood; Ellen Ypma; Maria Zambon
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

2.  Humoral and cell-mediated immunity to vero cell-derived influenza vaccine.

Authors:  P Brühl; A Kerschbaum; O Kistner; N Barrett; F Dorner; M Gerencer
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

3.  Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

Authors:  Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; Qiang Gao; Zhenshan Zhang; Yuxuan Liu; Zhihong Wang; Meng Yang; Ruihua Sun; Changgui Li; Su Lin; Mei Ji; Yan Liu; Xu Wang; John Wood; Zijian Feng; Yu Wang; Weidong Yin
Journal:  Lancet       Date:  2006-09-16       Impact factor: 79.321

4.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Authors:  K G Nicholson; A E Colegate; A Podda; I Stephenson; J Wood; E Ypma; M C Zambon
Journal:  Lancet       Date:  2001-06-16       Impact factor: 79.321

5.  Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Authors:  Jean-Louis Bresson; Christian Perronne; Odile Launay; Catherine Gerdil; Melanie Saville; John Wood; Katja Höschler; Maria C Zambon
Journal:  Lancet       Date:  2006-05-20       Impact factor: 79.321

6.  Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs.

Authors:  J S Robertson; C W Naeve; R G Webster; J S Bootman; R Newman; G C Schild
Journal:  Virology       Date:  1985-05       Impact factor: 3.616

7.  Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants.

Authors:  Tokiko Watanabe; Shinji Watanabe; Jin Hyun Kim; Masato Hatta; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

Review 8.  Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines.

Authors:  R J Cox; K A Brokstad; P Ogra
Journal:  Scand J Immunol       Date:  2004-01       Impact factor: 3.487

9.  Evidence for host-cell selection of influenza virus antigenic variants.

Authors:  G C Schild; J S Oxford; J C de Jong; R G Webster
Journal:  Nature       Date:  1983 Jun 23-29       Impact factor: 49.962

10.  The molecular basis of the specific anti-influenza action of amantadine.

Authors:  A J Hay; A J Wolstenholme; J J Skehel; M H Smith
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  32 in total

1.  An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus.

Authors:  Yasuko Hatta; Masato Hatta; Pamuk Bilsel; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  Role of the CM2 protein in the influenza C virus replication cycle.

Authors:  Takatoshi Furukawa; Yasushi Muraki; Takeshi Noda; Emi Takashita; Ri Sho; Kanetsu Sugawara; Yoko Matsuzaki; Yoshitaka Shimotai; Seiji Hongo
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

3.  Replication-incompetent influenza A viruses that stably express a foreign gene.

Authors:  Makoto Ozawa; Sylvia T Victor; Andrew S Taft; Shinya Yamada; Chengjun Li; Masato Hatta; Subash C Das; Emi Takashita; Satoshi Kakugawa; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2011-08-31       Impact factor: 3.891

4.  High level of genetic compatibility between swine-origin H1N1 and highly pathogenic avian H5N1 influenza viruses.

Authors:  Cássio Pontes Octaviani; Makoto Ozawa; Shinya Yamada; Hideo Goto; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.

Authors:  Michael J Moser; Yasuko Hatta; Claudia Gabaglia; Adriana Sanchez; Peter Dias; Sally Sarawar; Yoshihiro Kawaoka; Masato Hatta; Gabriele Neumann; Pamuk Bilsel
Journal:  Vaccine       Date:  2019-07-04       Impact factor: 3.641

6.  Influenza H1N1 A/Solomon Island/3/06 virus receptor binding specificity correlates with virus pathogenicity, antigenicity, and immunogenicity in ferrets.

Authors:  Qi Xu; Weijia Wang; Xing Cheng; James Zengel; Hong Jin
Journal:  J Virol       Date:  2010-03-03       Impact factor: 5.103

7.  M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice.

Authors:  Sally Sarawar; Yasuko Hatta; Shinji Watanabe; Peter Dias; Gabriele Neumann; Yoshihiro Kawaoka; Pamuk Bilsel
Journal:  Vaccine       Date:  2016-09-03       Impact factor: 3.641

Review 8.  Inflammasomes as mediators of immunity against influenza virus.

Authors:  Iris K Pang; Akiko Iwasaki
Journal:  Trends Immunol       Date:  2010-12-14       Impact factor: 16.687

Review 9.  Viral miniproteins.

Authors:  Daniel DiMaio
Journal:  Annu Rev Microbiol       Date:  2014-04-10       Impact factor: 15.500

10.  Induction of CD8 T cell heterologous protection by a single dose of single-cycle infectious influenza virus.

Authors:  Hailong Guo; Steven F Baker; Luis Martínez-Sobrido; David J Topham
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.